European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx



Contents lists available at ScienceDirect European Journal of Pharmaceutics and Biopharmaceutics

journal homepage: www.elsevier.com/locate/ejpb

Research paper

Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration

Guadalupe Abrego^{a,b}, Helen Alvarado^{a,b}, Eliana B. Souto^{c,d,*}, Bessy Guevara^b, Lyda Halbaut Bellowa^e, Alexander Parra^{a,b}, Ana Calpena^b, María Luisa Garcia^{a,*} 8 9

10 ^a Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain 11

^b Department of Biopharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain

^c Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Coimbra, Portugal 12 13

^d Center for Neuroscience and Cell Biology & Institute for Biomedical Imaging and Life Sciences (CNC-IBILI), University of Coimbra, Pólo das Ciências da Saúde, Coimbra, Portugal

^e Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain

ARTICLE INFO

58

5

38 20 Article history: 21 Received 24 November 2014 22 Accepted in revised form 28 January 2015 23 Available online xxxx 24 Chemical compounds: 25 Pranoprofen (PubChem CID:4888) 26 27 Keywords: 28 Pranoprofen 29 Nanoparticles 30 Hydrogel 31 Ocular tolerance 32 Physical stability 33 Corneal permeation 34 Anti-inflammatory efficacy 35 Azone 36

Non-steroidal anti-inflammatory drug

ABSTRACT

Two optimized pranoprofen-loaded poly-1-lactic-co glycolic acid (PLGA) nanoparticles (PF-F1NPs; PF-F2NPs) have been developed and further dispersed into hydrogels for the production of semi-solid formulations intended for ocular administration. The optimized PF-NP suspensions were dispersed in freshly prepared carbomer hydrogels (HG_PF-F1NPs and HG_PF-F2NPs) or in hydrogels containing 1% azone (HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone) in order to improve the ocular biopharmaceutical profile of the selected non-steroidal anti-inflammatory drug (NSAID), by prolonging the contact of the pranoprofen with the eye, increasing the drug retention in the organ and enhancing its anti-inflammatory and analgesic efficiency. Carbomer 934 has been selected as gel-forming polymer. The hydrogel formulations with or without azone showed a non-Newtonian behavior and adequate physicochemical properties for ocular instillation. The release study of pranoprofen from the semi-solid formulations exhibited a sustained release behavior. The results obtained from ex vivo corneal permeation and in vivo anti-inflammatory efficacy studies suggest that the ocular application of the hydrogels containing azone was more effective over the azone-free formulations in the treatment of edema on the ocular surface. No signs of ocular irritancy have been detected for the produced hydrogels.

© 2015 Elsevier B.V. All rights reserved.

63

64

65

66

67

68

69

70

71

72

73

74

39

40

41

Abbreviations: PF, pranoprofen; NPs, nanoparticles; HG, hydrogel; PF-F1NPs and PF-F2NPs, optimize pranoprofen nanoparticles; HG_PF-NPs-Azone and HG_PF-NPs, nanoparticles incorporated into hydrogel with and without azone, respectively; Z-Ave, average particle size; PI, polydispersity index; ZP, zeta potential; EE, entrapment efficiency; PVA, polyvinyl alcohol; cPF, PF concentration; cPVA, PVA concentration; PLGA, poly-L-lactic-co glycolic acid; cPLGA, PLGA concentration; SA, arachidonic acid sodium; PBS, phosphate buffer solution; BR, Bicarbonate Ringer; Q_P , amounts of drug permeated across cornea; Q_R , amounts of drug retained in the

cornea. * Corresponding authors. Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal. Tel.: +351 239 488 400; fax: +351 239 488 503 (E.B. Souto). Department of Physical Chemistry, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain. Tel.: +34 934 021 220; fax: +34 934 021 231 (M.L. Garcia).

E-mail addresses: ebsouto@ff.uc.pt (E.B. Souto), marisagarcia@ub.edu (M.L. Garcia).

http://dx.doi.org/10.1016/j.ejpb.2015.01.026 0939-6411/© 2015 Elsevier B.V. All rights reserved.

1. Introduction

Pranoprofen is a non-steroidal anti-inflammatory drug (NSAID) which can be used as a safe and effective alternative anti-inflammatory treatment following strabismus and cataract surgery [1-3]. This drug has the beneficial effect of reducing the ocular signs and symptoms of dry eye and decreasing the inflammatory markers of conjunctival epithelial cells [4]. Its efficacy is equivalent to moderate-potency corticosteroids, but it has improved safety profile. It should be considered for the treatment of chronic conjunctivitis of presumed nonbacterial origin [5]. Although this drug has shown high anti-inflammatory and analgesic efficiency, the pharmaceutical use of pranoprofen is limited due to its inadequate biopharmaceutical profile. Pranoprofen has a short plasmatic halflife, low water solubility and is unstable in aqueous solution, particularly when exposed to light [6,7]. Pranoprofen is commercially available as eye-drops (0.1% m/V). However, this conventional dos-

148

149

160

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190 191

2

G. Abrego et al. / European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

75 age form cannot be considered optimal in the treatment of ocular 76 diseases due to the fact that upon instillation most of the drugs 77 are removed from the surface of the eye, by various mechanisms 78 (tear dilution and tear turn over). Moreover, the relatively imper-79 meable corneal barrier restricts the entry of foreign substances. 80 As a result, less than 5% of the administered drug penetrates the 81 cornea and reaches intraocular tissue [8]. Polymeric NPs are one 82 of the colloidal systems that have been most widely studied over 83 the past few decades with the objective of improving drug targeting of tissues and organs and increase drug bioavailability across 84 85 biological membranes. Biodegradable polymers, such as poly (lac-86 tic-co-glycolic) acid (PLGA), have been widely used in drug delivery research, in part due to their approval by the FDA for use in 87 humans and they can effectively deliver the drug to a target site 88 89 with a controllable degradation [9]. PLGA can be used such as 90 matrix to load different drugs for topical administration [10–12].

91 Different drug delivery systems have been studied in order to 92 improve drug targeting of tissues, increase drug bioavailability 93 across biological membranes or reducing its toxicity. For topical application of nanoparticle suspensions, several of these systems 94 95 have been dispersed in semi-solid vehicles such as hydrogels or 96 cream [13,14]. Among the gelling agents, carbomer has been 97 extensively used for design topical formulations [15-17]. In addi-98 tion, to improve the permeability of drugs through the ocular bar-99 riers, different enhancers have also been tested. Azone is one of the 100 most widely studied penetration enhancers which can be used as a 101 safe and effective penetration enhancer for human use in the range 102 of 1–10% [18]. In previous studies, we have formulated pranoprofen in PLGA nanoparticles (PF-NPs) using the solvent displacement 103 technique [19]. A 2⁴ central composite factorial design has been 104 applied to study the main effects and interactions of four factors 105 on average particle size (Z-Ave), polydispersity index (PI), zeta 106 107 potential (ZP) and entrapment efficiency (EE). The factors studied 108 were PF concentration (cPF), PVA concentration (cPVA), PLGA 109 concentration (cPLGA) and aqueous phase pH. From a total of 26 110 formulations obtained by factorial design, two optimum formula-111 tions (PF-F1NPs and PF-F2NPs) were selected for further investiga-112 tion here [20]. The aim of this study was designed semi-solid 113 formulations containing pranoprofen loaded-PLGA nanoparticles 114 for ocular administration. Carbomer 934 was selected to disperse 115 the optimized PF-NP suspension because of the bioadhesive properties, low or no toxicity, rheological characteristics and biocom-116 patibility of the hydrophilic polymer. Polyacrylic acid hydrogels 117 118 such as Carbomer 934, polycarbophil and carboxymethylcellulose have been reported as the most appropriate bioadhesive polymers 119 120 for ocular drug delivery [21]. Additionality, the high viscosity of the 121 carbomer hydrogels ensures the prolonged retention improving 122 the ocular bioavailability of some drugs [22]. The optimized PF-123 F1NP and PF-F2NP suspensions were dispersed into blank hydro-124 gels (HG_PF-F1NPs and HG_PF-F2NPs) or in hydrogels containing 125 1% azone (HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone) in order to improve the biopharmaceutical profile of pranoprofen in the 126 eye, by increasing is ocular retention and improving the anti-127 inflammatory and analgesic efficiency. The ultimate aim of the 128 129 developed formulations is to improving the patient's compliance to the pharmacological treatment by reducing the application fre-130 131 quency. In this study, azone was selected as permeation enhancer with the purpose to improve the permeability of pranoprofen from 132 PF-NPs based HG through the ocular barriers. Azone is one of the 133 134 most widely studied penetration enhancers for hydrophilic and 135 lipophilic drugs. As a penetration enhancer, azone is more effective 136 at low percentages (1-3%), and it has also been reported to be of 137 low irritancy and very low toxicity [23]. The mechanism of azone 138 may be related to some changes in the epithelial cell junctions of 139 the cornea, which are nevertheless reversible in cornea structure 140 [24,25].

The physicochemical properties and the rheological behavior of141HG_PF-NP formulations have been characterized. The physical sta-142bility of the nanoparticles incorporated into hydrogels has also143been evaluated. In vitro release profile and ex vivo corneal perme-144ation of pranoprofen from the semi-solid formulations, as well as145their in vitro e in vivo ocular tolerance and the anti-inflammatory146efficacy have also been assayed.147

2. Materials and methods

2.1. Materials

Pranoprofen and Oftalar[®] were kindly supplied by Alcon Cusi 150 (Barcelona, Spain); PLGA Resomer[®] 753S was obtained from Boeh-151 ringer Ingelheim (Ingelheim, Germany). Polyvinyl alcohol (PVA) 152 with 90% hydrolyzation and Arachidonic acid sodium (SA) were 153 obtained from Sigma Aldrich (St. Louis, USA). Gel-forming polymer 154 (Carbomer 934) was obtained from Fagron Ibérica. The purified 155 water used in all the experiments was obtained from a MilliQ Sys-156 tem. All the other chemicals and reagents used in the study were of 157 analytical grade. 158

2.2. Methods 159

2.2.1. Preparation of pranoprofen-loaded nanoparticles

The nanoparticles have been produced by the solvent displace-161 ment technique, described by Fessi et al. [19]. PLGA (90 mg or 162 95 mg) and pranoprofen (10 mg or 15 mg) were dissolved in 163 5 mL of acetone. This organic phase was poured, under moderate 164 stirring into 10 mL of an aqueous solution of PVA (5 mg/mL or 165 10 mg/mL) adjusted to the desired pH value (4.5 or 5.5). The ace-166 tone was then evaporated and the dispersed nanoparticles were 167 concentrated to 10 mL under reduced pressure (Büchi B-480 Fla-168 wil, Switzerland). Table 1 shows the composition of the optimized 169 pranoprofen-loaded nanoparticles. 170

2.2.2. Mean particle size and zeta potential

The mean particle size (Z-Ave) and the zeta potential (ZP) of the nanoparticles were determined by photon correlation spectroscopy (PCS) with a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) at 25 °C using disposable quartz cells and disposable folded capillary zeta cells (Malvern Instruments, Malvern, UK), respectively. For all measurements, the samples were diluted with MilliQ water (1:20). The reported values are the mean ± SD of at least three different batches of each formulation.

2.2.3. Encapsulation efficiency

The encapsulation efficiency (EE) of pranoprofen in the nanoparticles was determined indirectly by measuring the concentration of the free drug in the dispersion medium. The non-encapsulated pranoprofen was separated using a filtration/ centrifugation technique with Ultracel-100K (Amicon[®] Ultra, Millipore Corporation, Billerica, MA) centrifugal filter devices at 3000 rpm for 30 min at 4 °C (Heraeus, Multifuge 3 L-R, centrifuge. Osterode, Germany). Each sample was diluted with MilliQ water (1:20) prior to filtration/centrifugation. The EE was calculated using the following equation:

Table 1
Composition of the optimized pranoprofen-loaded nanoparticles.

PF-NPs	cPF (mg/mL)	cPVA (mg/mL)	cPLGA (mg/mL)	pН
PF-F1NPs	1.5	10.0	9.5	5.5
PF-F2NPs	1.0	5.0	9.0	4.5

G. Abrego et al./European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

$$EE(\%) = \frac{\text{Total Amount of pranoprofen} - \text{Free drug}}{\text{Total Amount of pranoprofen}} \times 100$$
(1)

194 The assay was carried out by high performance liquid chroma-195 tography (HPLC) using a method previously validated in our labo-196 ratory. The detection and quantification limits (LOD and LOQ) found for the validated method were $1.05 \pm 0.70 \,\mu\text{g/mL}$ and 197 $3.17 \pm 2.12 \,\mu\text{g/mL}$, respectively. The HPLC system consisted of a 198 Waters 1525 pump (Waters, Milford, USA) with a UV-Vis 2487 199 200 detector (Waters), a flow rate of 1 mL/min and wavelength of 245 nm were used with a (Kromasil[®], 100-5C18, $4.6 \times 100 \text{ mm}$) 201 column. The mobile phase consisted of methanol: glacial acetic 202 acid 5% (45: 55, v: v). 203

204 2.3. Preparation of pranoprofen-loaded nanoparticles dispersed in 205 hydrogels

206 The blank hydrogels were prepared with carbomer (1% w/v), 207 dispersed in purified water and allowed to hydrate for 24 h. Subse-208 quently, glycerol (3% w/w) and azone (0% or 1% w/w) were incorporated into the hydrogel by stirring for 5 min at 1000 rpm in a 209 210 high speed stirred (Cito Unguator Konietzko, Bamberg, Germany) and then the pH was adjusted at 6.5 with 0.1 N NaOH. The HG 211 was left to equilibrate for 24 h at room temperature before used. 212 213 The optimized aqueous PF-NP suspensions were incorporated into HG with 0% or 1% azone using a high speed stirred by 3 min at 214 1000 rpm, in a concentration of 50% (w/w) of the nanoparticle dis-215 persion into the hydrogel. 216

217 2.4. Physicochemical characterization of the hydrogels

218 The morphological examination of the NPs incorporated into 219 HG was performed by Transmission Electron Microscopy (TEM). 220 The sample was dispersed in MilliQ water using an Elma Trans-221 sonic Digital S T490 DH ultrasonic bath (Elma, Singen, Germany). A drop of this dispersion $(10 \,\mu\text{L})$ was placed on copper electron 222 microscopy grids and stained with a 2% (w/v) uranyl acetate solu-223 tion. After 1 min, the sample was washed with ultra-purified water 224 225 and the excess fluid removed with a piece of filter paper. The dried 226 sample was then examined.

227 The physical stability of the HG_PF-NP formulations was assessed after 1 day of the production and 90 days of storage at 228 229 25 °C. The Z-Ave and ZP of the particles were determined by pho-230 ton PCS as described above. The diameter of the nanoparticles dis-231 persed into the hydrogels also was measured by laser diffraction (LD) data, obtained with a Mastersizer Hydro 2000MU (Malvern 232 233 Instruments Ltd., Malvern, UK), using the volume distribution as 234 diameter values of LD 10%, LD 50% and LD 90%. The diameter values indicate the percentage of nanoparticles showing a diameter equal 235 or lower than the given value. For all measurements, the samples 236 237 were dispersed in MilliQ water using an Elma Transsonic Digital 238 S T490 DH ultrasonic bath (Elma, Singen, Germany).

239 2.5. Rheological measurements of the hydrogels

240 The hydrogel samples were placed in glass vials with rubber top 241 and aluminum capsule and storage at 25 °C ± 2 °C. The rheological characterization of each formulation was performed using a Haake 242 Rheostress1 rheometer (Thermo Fisher Scientific, Karlsruhe, 243 244 Germany) connected to a temperature control Thermo Haake 245 Phoenix II + Haake C25P and equipped with parallel plate geometry (Haake PP60 Ti, 60 mm diameter, 0.5 mm gap between plates) 246 or cone plate set-up with a fixed lower plate and a mobile upper 247 248 cone (Haake C35/2° Ti, 35 mm diameter, 0.106 mm gap between 249 cone-plate). The viscosity curves and flow curves were recorded 250 under rotational runs at 25 °C for 3 min during the ramp-up period from 0 to 100 s⁻¹, 1 min at 100 s⁻¹ (constant share rate period) and finally 3 min during the ramp-down period from 100 to 0 s⁻¹. Viscosity values at 100 s⁻¹ were determined after 8 days of the production and 90 days of storage at 25 ± 2 °C, in three replicates. Oscillatory stress sweep tests were performed at a constant frequency of 1 Hz in a stress range of 0.1 and 200 Pa. Oscillation frequency tests were carried out from 0.01 to 10 Hz at a constant shear stress within the linear viscoelastic region, in order to determine the related variation of storage modulus (G') and loss modulus (G") at 25 °C. The software Haake RheoWin[®] Job Manager V.3.3 and RheoWin[®]Data Manager V.3.3 (Thermo Electron Corporation, Karlsruhe, Germany) were used to carry out the test and analysis of the obtained data, respectively.

2.6. In vitro pranoprofen release from the hydrogels

In vitro release study of pranoprofen from the HG_PF-NP formulations was performed in Franz diffusion cells [26]. These cells consist of a donor and a receptor chamber between which a membrane is positioned. A dialysis membrane (MWCO 12,000-14,000 Da., Dialysis Tubing Visking, Medicell International Ltd., London, UK) was used. The membrane was hydrated for 24 h before being mounted in the Franz diffusion cell. The experiment was performed under "sink condition". The HG_PF-NP formulations were compared with the commercial eye drops (Oftalar[®], pranoprofen 1 mg/mL) and the free drug (1 mg/mL) dissolved in phosphate buffer solution (PBS) at pH 7.4. A weight of 400 mg of the HG_PF-NP formulations or a volume of 200 µL of the free drug solution and commercial eye drops was placed in the donor compartment and the receptor compartment was filled with PBS at pH 7.4 kept at 37 ± 0.5 °C. A volume of 300 µL was withdrawn from the receptor compartment at fixed times and replaced by an equivalent volume of fresh PBS at the same temperature. The concentration of pranoprofen released was measured as described previously for EE. Values are reported as the mean ± SD of three replicates.

The amount pranoprofen release was adjusted to the following kinetic models [27]:

Zero order : $\% R_t / \% R_\infty = k \times t$	(2)	
First order : $\% R_t / \% R_\infty = 1 - e^{-k \times t}$	(3)	
Higuchi : $\% R_t / \% R_\infty = k \times t^{1/2}$	(4)	
Hyperbola : $\Re R_t / \Re R_\infty = R_\infty \times t / (k+t)$	(5)	
Korsmeyer–Peppas : $\Re R_t / \Re R_\infty = k \times t^n$	(6)	288

where R_t is the percentage of the drug released at time *t*, R_∞ is the total percentage of drug released, R_t/R_{∞} is the fraction of 290 drug released at time t, k is the release rate constant and n is the dif-291 292 fusion release exponent that can be used to characterize the differ-293 ent release mechanisms; $n \le 0.5$ (Frickian diffusion), 0.5 < n < 1.0294 (anomalous transport), and $n \ge 1$ (case II transport, i.e., zero-order 295 release). A nonlinear least-squares regression was performed using the WinNonLin[®] software (WinNonLin[®] professional edition version 296 3.3 and Graphpad prism version 6 Demo) and the model parameters 297 were calculated. Akaike's information criterion (AIC) was deter-298 mined for each model as an indicator of the model's suitability for 299 a given dataset [28].

2.7. Corneal permeation study

Ex vivo corneal permeation experiments were carried out with 302 New Zealand rabbits (male, weighing 2.5–3.0 kg), under veterinary 303 supervision and according to the Ethics Committee of Animals 304 Experimentation at the University of Barcelona. The rabbits were 305 anesthetized with intramuscular administration of ketamine HCl 306 (35 mg/kg) and xylazine (5 mg/kg). The animals were euthanized 307

Please cite this article in press as: G. Abrego et al., Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpb.2015.01.026

3

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

289

300

G. Abrego et al. / European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

308 by an overdose of sodium pentobarbital (100 mg/kg) administered 309 through marginal ear vein under deep anesthesia. The corneas, 310 with 2 mm ring of sclera were excised and immediately trans-311 ported to the laboratory in artificial tear solution. The assay was 312 done using Franz diffusion Cells. The cornea was fixed between 313 the donor and receptor compartment of Franz cell. The corneal area 314 available for permeation was 0.64 cm². The receptor compartment 315 was filled with freshly prepared Bicarbonate Ringer's (BR) solution. This compartment was kept at 37 ± 0.5 °C and stirred continuously. 316 A weight of 1 g of the HG_PF-NP formulations or 1 mL of the com-317 mercial eye drops and free drug solution was placed in the donor 318 319 compartment (covered with parafilm[®] in order to avoid evaporation). A volume of 300 µL was withdrawn from the receptor com-320 partment at fixed times and replaced by an equivalent volume of 321 322 fresh BR solution at the same temperature. The cumulative prano-323 profen amount permeated through the cornea per unit area (µg/ 324 cm^2) was calculated, at each time point, from cPF in the receiving 325 medium and plotted as function time (min).

2.8. Amount of pranoprofen retained in the cornea 326

327 At the end of the study, the cornea was used to determine the amount of drug retained. The cornea was carefully freed from the 328 329 sclera ring, cleaned using a 0.05% solution of sodium lauryl sulfate 330 and washed with distilled water, weighed and treated with meth-331 anol: water (50:50, V/V) under sonication during 30 min using an 332 ultrasound bath. The amount of pranoprofen permeated and 333 retained through the cornea was determined by HPLC as described 334 previously for EE. The results are reported as the median ± SD and 335 median value (minimum - maximum range) of six and three rep-336 licates for the amount of pranoprofen permeated and retained, 337 respectively.

338 2.9. Ocular permeation parameter

345

347

366

339 Lag time T_L (h) values were calculated by plotting the 340 cumulative pranoprofen permeating the cornea versus time, 341 determining x-intercept by linear regression analysis. The corneal 342 permeability coefficient K_P (cm/h), partition coefficient P_1 (cm) 343 and diffusion coefficient P_2 (h⁻¹) were calculated from the 344 following equations:

$$K_P = P_1 \times P_2$$

$$P_1 = J/(A \times C_0 \times P_2)$$

$$P_2 = 1/(6 \times T_L)$$
(7)
(8)
(9)

348 where C_0 is the initial concentration of drug in the donor compart-349 ment, $A(0.64 \text{ cm}^2)$ is the exposed corneal surface. All the values are 350 reported as median value (minimum - maximum range) of three 351 replicates. Experimental data were processed using Graphpad prism 352 software (version 6 Demo) and compared by the application of a 353 non-parametric statistical Kruskal-Wallis Z test followed by the 354 Dunn's multiple comparison tests. Values were considered to be 355 significant at p < 0.05.

356 2.10. Corneal hydration levels

The corneal hydration level HL (%) of the cornea was deter-357 mined at the end of the study of corneal permeation. The cornea 358 was carefully freed from the sclera ring, washed, weighed (W_w) 359 360 and dessicated at constant weight dried at 80 °C and then reweighed (W_d) . The HL values are reported as median value (min-361 imum - maximum range) of three replicates. HL was calculated 362 using the following expression: 363 364

$$HL = [1 - (W_d/W_w) \times 100]$$

2.11. In vitro ocular tolerance

The ocular tolerance of the HG PF-NP formulations with a 0% or 368 1% azone was assessed by the HET-CAM test. This is an alternative 369 to animal testing (Draize test) described by Luepke [29]. To per-370 form it, the shell and the inner membranes of 10-day-old chicken 371 eggs were previously removed, so that the CAM that separates 372 the embryo from the air chamber was visible, according to the 373 Invittox protocol [30], and the Journal officiel de la République 374 Française [31]. Tolerance was assessed by testing 6 eggs for each 375 sample, using 2 eggs treated with 0.1 N NaOH and 2 treated with 376 1% sodium lauryl sulfate solution as positive controls. After expos-377 ing the CAM and rinsing it with PBS at pH 7.4, 300 µL of the test 378 solution was applied to the CAM. The intensity of the reaction 379 was semi-quantitatively assessed on a scale from 0 (no reaction) to 3 (strong reaction). The time of the appearance and the intensity of any reactions that occurred within 5 min were recorded. The 382 ocular irritation index (OII) was then calculated using the following 383 equation:

$$OII = \frac{(301 - h) \times 5}{300} + \frac{(301 - l) \times 7}{300} + \frac{(301 - c) \times 9}{300}$$
(11) 387

where *h* is the time (in seconds) until the start of a hemorrhage, *l* 388 until the start of lysis and *c* until the coagulation. The following 389 classification was used: OII \leq 0.9: slightly irritating; 0.9 \leq OII \leq 4.9: 390 moderately irritating; $4.9 \le OII \le 8.9$: irritating; $8.9 \le OII \le 21$: severely irritating.

2.12. In vivo ocular tolerance

The irritancy of the HG_PF-NP formulations with a 0% or 1% 394 azone was evaluated in New Zealand white rabbits (2.5-3.0 kg) following the method described by Draize et al.[32,33] A single instil-396 lation of 50 µL of each HG_PF-NP formulation was instilled in one 397 eye, using untreated contra-lateral eye as a control. Readings were 398 performed 1 h after sample application, then after 1, 2, 3, 4 and 399 7 days. The method provided an overall scoring system for grading 400 the severity of ocular lesions involving the cornea (opacity), iris 401 (inflammation degree) and conjunctiva (congestion, swelling and 402 discharge). The Draize score was determined by visual assessment 403 of change in these ocular structures. The mean total score (MTS) 404 was calculated as follows: 405 406

$$MTS = \frac{X_1(n)}{2} + \sum \frac{X_2(n)}{2} - \sum \frac{X_3(n)}{5}$$
(12) 408

where $x_1(n)$, $x_2(n)$ and $x_3(n)$ are the cornea, conjunctiva and iris 409 scores, respectively, being n the number of rabbits included in the 410 ocular tolerance assay. 411

2.13. In vivo anti-inflammatory efficacy

The anti-inflammatory efficacy of the HG_PF-NP formulations 413 was assessed using the method described by Spampinato Santi 414 et al. [34], the ocular inflammation was induced by ocular instilla-415 tion of 50 μ L SA (dissolved in PBS, 0.5% (w/v)) in the right eye of 416 eight groups of six rabbits (including control group). A volume of 417 50 µL of each HG_PF-NP formulation or 0.9% (w/v) isotonic saline 418 solution (control group) was instilled in the conjunctival sac of 419 the right eye 30 min before induction of ocular inflammation by 420 SA using left eye as an inflammation control. Inflammation was 421 quantified 30 min after AS instillation, then after 60, 90, 120, and 422 150 min, according to a modified Draize scoring system [32]. The 423 MTS was calculated as described previously in the ocular tolerance 424 assay (Eq. (12)). Since corneal transparency was not affected by the 425 instillation of SA, this parameter was not considered. The sum of 426 the conjunctival and iris score is expressed by the mean ± SD. 427

380 381

367

384 385

391 392

395

412

393

Please cite this article in press as: G. Abrego et al., Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpb.2015.01.026

(10)

G. Abrego et al./European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

428 3. Results and discussion

429 3.1. Physicochemical characterization of the HG_PF-NPs

In previous studies, we have formulated pranoprofen in PLGA 430 nanoparticles as new delivery system suitable for the ocular route. 431 432 The Z-Ave of the optimized PF-F1NP and PF-F2NP formulations was 433 around 350 nm with PI values in the range of mono-disperse sys-434 tems (PI < 0.1). Both formulations had net negative charge with 435 ZP values of – 7.41 mV and – 8.5 mV for PF-F1NPs and PF-F2NPs, 436 respectively. The percentage of encapsulated pranoprofen in the polymeric matrix for these formulations reached 80% [20]. For 437 438 the present work, carbomer 934 was selected as hydrogel matrix to incorporate the optimized PF-F1NP and PF-F2NP suspensions 439 in order to improve the biopharmaceutical profile of pranoprofen 440 for the ocular application. The size and surface morphology of 441 the optimized PF-NPs after incorporation into HG were determined 442 by TEM. The mean diameters of HG_PF-NP formulations were 443 around 300 nm. 444

TEM image depicted in Fig. 1 reveals that the optimized NPs after incorporation into HG were spherical shape and non-aggregated. The results obtained show that the Z-Ave of the NPs incorporated into HG was similar to those of the NP suspensions.

The stability of the nanoparticles dispersed into the hydrogels 449 was assessed after 1 day of the production and after 90 days of 450 storage at 25 °C. The results obtained by DL 1 day after the produc-451 452 tion reveal two peaks, one at about 400 nm and another small peak 453 at 1 µm for all the HG_PF-NP formulations indicating an increase of 454 the Z-Ave and PI of the PF-NPs after incorporated into the hydro-455 gels (see Fig. a, c, e and g in Supplementary materials). After 456 90 days of storage at 25 °C, an increase in the Z-Ave values com-457 pared with the results obtained 1 day after the production (see 458 Fig. b, d, f and h in Supplementary materials). The results given 459 in Table 2 show that the Z-Ave values obtained by PCS were similar to those obtained by DL. This increase in the apparent particle size 460 461 was attributed to the strong entrapment of the particles within the




Fig. 1. Transmission electron microphotograph of the optimized NPs incorporated into hydrogel.

tridimensional gel structure, rather than real particle agglomerates. These results are in accordance with those obtained by Gonzalez-Mira et al. [35]. These results are also in agreement with those obtained by TEM (Fig. 1), since PF-NPs incorporated into HG showed similar particle size in comparison with PF-NP suspension and they were not aggregated. The particle size of formulations intended for ocular instillation is of crucial importance and it should not exceed 10 µm; larger sizes may cause a scratching feeling of a foreign body in the eye and it would therefore compromise patient's comfort [36,37]. The results obtained by PCS in Table 2 also revealed a significant increase of the ZP values of the PF-NPs after incorporated into hydrogels. These results were attributed to the adsorption of negatively charge of the jellifying agent molecules onto the surface of the particles [38]. All the results obtained from the stability study show that the HG_PF-NPs with or without azone formulations exhibit appropriates physicochemical properties for ocular administration, which indicates that the gel network of carbomer could not influence the morphology and size of the NPs notably.

3.2. Rheological measurements

The results obtained from the rheological characterization of the HG_PF-NP formulations with or without azone are shown in Table 3.

The rheological characterization of the HG PF-NP formulations with or without azone revealed a non-Newtonian behavior and the pseudo-plastic character. The spreading properties and the ability of controlling their viscosity showed for the HG PF-NPs are desirable for the ocular application. The results obtained in Table 3 show that the HG_PF-NP formulations after 90 days of storage at 25 °C exhibited a decreased of the viscosity and Thixotropy values regarding to the values observed at 8 days of the production. Table 3 also reveals that the inclusion of azone in the HG_PF-NP formulations leads a significant viscosity increase in the HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone formulations. These results are in accordance with the increase of the Z-Ave and PI obtained after 90 days of storage at 25 °C obtained by LD (see Figure in Supplementary material) and PCS (Table 2) which could be explained by the fact that the NPs characterized by a wide polydispersity could pack better than those with a narrow polydispersity. The particles with a large polydispersity have more free space to move around, which means that it was easier for the sample to flow and a lower viscosity would be measured [39].

The oscillation frequency test was carried out from 0.01 to 10 Hz at a constant shear stress within the linear viscoelastic region, in order to determine the related variation of storage modulus (G') and loss modulus (G'') at 25 °C, where the G' describes the elastic properties whereas G'' describes the viscous properties of the sample.

With respect to the stress sweep test of the oscillatory study, the critical stress was found at 10 Pa for the semi-solid formulations assayed. These results suggest that none of the formulations showed a weak structure. From the results of oscillatory stress sweeps, a constant shear stress of 2 Pa (20% of the critical value) was selected to perform the frequency sweep tests. The oscillatory measurements applied to the formulations showed the prevalence

Mean particle size (Z-Ave) and zeta potential (ZP) of the HG_PF-NP formulations 1 day after production and after 90 days of storage at 25 °C.

Time	HG_PF-F1NPs		HG_PF-F2NPs		HG_PF-F1NPs-Az	zone	HG_PF-F2NPs-Az	zone
Day	Z-Ave (nm)	ZP (mV)	Z-Ave (nm)	ZP (mV)	Z-Ave (nm)	ZP (mV)	Z-Ave (nm)	ZP (mV)
1 90	385.20 ± 0.21 495.70 ± 0.33	-27.50 ± 0.10 -28.80 ± 0.11	391.30 ± 0.22 471.50 ± 0.41	-37.80 ± 0.13 -39.4 ± 0.12	428.07 ± 0.13 549.63 ± 0.10	-34.20 ± 0.10 -37.77 ± 0.12	437.20 ± 0.10 479.57 ± 0.12	-31.87 ± 0.01 -37.63 ± 0.11
90	495.70±0.33	-28.80 ± 0.11	4/1.50 ± 0.41	-39.4 ± 0.12	549.63 ± 0.10	-37.77 ± 0.12	4/9.57±0.12	-37.03 ± 0.11

Please cite this article in press as: G. Abrego et al., Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpb.2015.01.026

5

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496 497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

16 February 2015

6

542

543

544

545

546

547

548

549

550

551

552

553

554

G. Abrego et al. / European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

Table	3
Tuble	•

Rheological characterization of the HG_PF-NP formulations after 8 and 90 days of storage at 25 °C.


Time	Time HG_PF-F1NPs		HG_PF-F2NPs		HG_PF-F1NPs-Azone		HG_PF-F2NPs-Azone	
Days	Viscosity (Pa s)	Thixotropy (Pa/s)	Viscosity (Pa s)	Thixotropy (Pa/s)	Viscosity (Pa s)	Thixotropy (Pa/s)	Viscosity (Pa s)	Thixotropy (Pa/s)
8 90	1.64 ± 0.002 1.10 ± 0.001	586.30 542.45	2.38 ± 0.001 0.93 ± 0.002	1935.03 555.10	2.70 ± 0.002 1.99 ± 0.001	3562.01 3290.63	2.95 ± 0.002 2.08 ± 0.002	3281.50 3061.30


of the elastic over the viscous behavior (G' > G'') for all the HG_PF-NP formulations.

519 3.3. In vitro drug release

520 An in vitro release study of pranoprofen from the HG_PF-NP formulations, free drug solution (pranoprofen, dissolved in PBS) and 521 522 commercial eye drops (Oftalar[®], pranoprofen 1.0 mg/mL) was performed in Franz diffusion cell. As shown in Fig. 2, the release profile 523 of pranoprofen from the free drug solution and the commercial eye 524 525 drops exhibited faster release than from the HG_PF-NP formulations with or without azone. After 3 h, 100% of the drug was 526 527 released from the free drug solution or commercial eye drops. 528 Fig. 2 reveals that the HG_PF-NP formulations with or without 529 azone exhibit a sustained release behavior. The accumulative 530 amount of pranoprofen released from HG_PF-F1NPs, HG_PF-F2NPs, HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone after 24 h 531 532 was 41.99%, 64.35%, 56.75% and 59.14%, respectively. Fig. 2 also shows that the amount released of pranoprofen from HG_PF-533 534 F1NPs and HG_PF-F1NPs-Azone was slightly smaller than HG_PF-535 F2NPs and HG_PF-F2NPs-Azone, respectively. These results might 536 be attributed to the fact that during the preparation of the NPs 537 the viscosity increases when there is an increase in the cPVA from 538 5 mg/mL (PF-F2NPs) to 10 mg/mL (PF-F1NPs). This viscosity 539 increase could result in a more compact polymer matrix leading 540 to slower degradation of the polymer or slower diffusion of the 541 loaded pranoprofen from the nanoparticles [40].

In previous studies, we assessed the release profile of pranoprofen from the PF-F1NP and PF-F2NP formulations. The results obtained from this study revealed that both formulations showed a sustained release behavior, with an initial burst attributed to the pranoprofen adsorbed onto the nanoparticles' surface, followed by a slower release phase while the trapped pranoprofen slowly diffuses out of the polymeric matrix into the release medium [20]. However, the pranoprofen release rate was faster from the pranoprofen-loaded nanoparticles than from the hydrogel formulations with or without azone. All these results suggest that the diffusion velocity of pranoprofen from the nanoparticles can be modified due to higher viscosity of the hydrogels respect to the nanoparticle suspensions. Nevertheless, the pranoprofen-loaded





nanoparticles or hydrogels with or without azone could offer sustained release of the drug in comparison with the free drug solution or commercial eye drops.

The amount of pranoprofen released from the HG_PF-F1NPs, HG_PF-F2NPs, HG_PF-F1NPs-Azone, HG_PF-F2NPs-Azone, commercial eye drops and free drug solution was adjusted to various kinetic models, such as zero-order, first-order, Higuchi, Hyperbola and Korsmeyer–Peppas (Table 4). The AIC was determined for each model. This parameter is an indicator of the model's suitability for a given dataset. The smaller the value of AIC, the better the model adjusts the data.

From the AIC values (Table 4), it can be concluded that the release curves of pranoprofen from HG_PF-F1NPs, HG_PF-F2NPs, HG_PF-F2NPs-Azone, commercial eye drops and free drug solution fitted to the hyperbola model very well. The drug release mechanism of the HG_PF-F1NPs-Azone formulation differed respect to the other formulations, which adjusted to the first order model. These models had the smaller AIC value and, therefore, statistically, described best the drug release mechanism. Taking into account the diffusional exponent value (n) that is used to characterize different release mechanisms, *n* values ≤ 0.5 were obtained in all the investigated HG_PF-NP formulations indicating that the release of pranoprofen from the semi-solid formulations occurs by passive diffusion. All these results suggest that the main factors that govern the release of the pranoprofen from the HG_PF-NP formulations with or without azone are the amount of PVA present in the formulation. Furthermore, the release rate is influenced by the presence of pranoprofen in crystalline form, since the drug in crystalline form should dissolve first before being transported out to the matrix by diffusion. As previously reported, in our study that the intensity of some of the peaks of crystalline pranoprofen present in the nanoparticles slightly increased when the concentration of the drug increased from 1.0 mg/mL (PF-F2NPs) to 1.5 mg/mL (PF-F1NPs) by X-ray diffraction technique [20]. Additionally, the drug diffusion out of a hydrogel matrix dependent on mechanical strength degradability, diffusivity, and other physical properties of hydrogel network [41].

3.4. Corneal permeation study

Ex vivo corneal permeation study has been carried out up to 6 h, to compare the permeation profile of pranoprofen from the hydrogel formulations with or without azone, commercial eye drops and free drug solution, and the results are shown in Fig. 3. The permeation parameter values are summarized in Table 5.

At the end of the corneal permeation study, the cornea was used to determine the amount of drug retained and the corneal hydration level. These results are exhibited in Table 6.

The corneal permeation parameters of pranoprofen calculated from the amounts of permeated across cornea from the hydrogel formulations with or without azone, commercial eye drops and free drug solution in Table 5 were compared by the application of a non-parametric statistical Kruskal–Wallis Z test followed by the Dunn's multiple comparison tests. From the statistical analysis of the K_P parameter obtained from these formulations, statistically significant differences (p < 0.05) were found between HG_PF-F1NPs and HG_PF-F2NPs, HG_PF-F1NPs and commercial eye drops,

555

556

557

558

573 574 575

572

583

584

585

586

587

588

589

590

591

592

593

594

605

606

607

608

609

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

Table 4

 Mean parameter obtained after fitting the release data of HG_PF-F1NPs, HG_PF-F2NPs, HG_PF-F1NPs-Azone, HG_PF-F2NPs-Azone, commercial eye drops and free drug solution to different kinetic models.

 Models
 Parameters
 HG_PF-F1NPs
 HG_PF-F2NPs
 HG_PF-F2NPs-Azone
 Eye drops
 Free drug

Models	Parameters	HG_PF-F1NPs	HG_PF-F2NPs	HG_PF-F1NPs-Azone	HG_PF-F2NPs-Azone	Eye drops	Free drug
Zero order	AIC	75.35	80.67	86.52	88.03	110.78	109.76
First Order	AIC	9.40	33.32	-7.46	37.01	70.48	67.21
Higuchi	AIC	55.12	52.86	69.11	71.01	101.97	102.63
Hyperbola		7.35	-8.23	26.99	15.96	59.36	50.52
Korsmeyer-	п	0.50	0.50	0.50	0.50	0.38	0.28
Peppas	AIC	55.20	53.22	69.20	72.62	110.27	115.37

n, diffusional release exponent; AIC, Akaike information criterion.




Fig. 3. *Ex vivo* corneal permeation profile of PF from the HG_PF-F1NPs, HG_PF-F2NPs, HG_PF-F2NPs, HG_PF-F2NPs-Azone formulations, commercial eye drops and free drug solution after 6 h. Mean \pm SD, *n* = 6. (For the interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

610 HG_PF-F1NPs-Azone and HG_PF-F2NPs, HG_PF-F1NPs-Azone and 611 commercial eye drops. The HG_PF-F1NPs and HG_PF-F2NPs show 612 the lowest and highest K_P value, respectively. Statistically signifi-613 cant differences (p < 0.05) were found between HG_PF-F1NPs and 614 HG_PF-F2NPs, HG_PF-F1NPs and commercial eye drops, HG_PF-

615 F1NPs and free drug, HG_PF-F2NPs-Azone and free drug, HG_PF-

F1NPs-Azone and commercial eye drops, HG_PF-F1NPs-Azone and free drug for the P_1 parameter. As shown in Table 5 the free drug solution and HG_PF-F1NPs formulation exhibited the highest and lowest P_1 value, respectively. The statistical analysis of the P_2 and T_L parameters in Table 5 revealed a significant difference (p < 0.05) between HG_PF-F1NPs and commercial eye drops, HG_PF-F1NPs and free drug, HG_PF-F2NPs-Azone and free drug, HG_PF-F1NPs-Azone and commercial eve drops, HG_PF-F1NPs-Azone and free drug. The HG_PF-F1NP formulation exhibits the highest P_2 value and the lowest P_1 value, thus this formulation shows the lowest K_P value, since K_P depends directly of P_1 and P_2 . The K_P values obtained for the HG_PF-F2NP formulation, commercial eye drops and free drug solution are directly related to the P_1 parameter. Otherwise, the P2 values exhibited for the HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone suggest that the diffusion coefficient of a drug is influenced by the presence of azone in the formulation. The T_L values obtained in Table 5 for the HG_PF-NPs with or without azone are lower than those obtained for the commercial eye drops and free drug solution. Therefore, these formulations reach faster the steady state equilibrium than the commercial eye drops and free drug solution.

The Q_P and Q_R values obtained for the commercial eye drops and free drug solution are greater than those obtained for the hydrogel

Table 5

Corneal permeation parameters of PF from HG_PF-NP formulations, commercial eye drops and free drug solution after 6 h.

Samples	$K_P \times 10^2 (\text{cm/h})$	$P_1 \times 10^1 ({\rm cm})$	$P_2 imes 10^1 \ (h^{-1})$	$TL \times 10^1$ (h)
HG_PF-F1NPs	1.50 (1.32–1.72) ^{b,e}	0.05 (0.04–0.05) ^{b,e,f}	32.64 (24.61-40.67) ^{e,f}	0.54 (0.41-0.68) ^{e,f}
HG_PF-F2NPs	5.56 (4.10-7.03) ^{a,c}	$0.61 (0.53 - 0.69)^{a}$	8.98 (7.80-10.16)	1.90 (1.64-2.14)
HG_PF-F1NPs-Azone	2.68 (2.62–2.72) ^{b,e}	0.11 (0.08–0.14) ^{e,f}	25.87 (18.09-33.66) ^{e,f}	0.71 (0.50–0.92) ^{e,f}
HG_PF-F2NPs-Azone	3.26 (3.27-3.29)	0.20 (0.16-0.24) ^f	16.93 (13.39–20.47) ^f	$1.03(0.81 - 1.25)^{f}$
Eye drops	3.46 (3.42–3.62) ^{a,c}	0.89 (0.77–0.91) ^{a,c}	3.98 (3.87–4.47) ^{a,c}	4.19 (3.73–4.31) ^{a,c}
Free drug	3.32 (3.28-3.56)	1.00 (0.93–1.07) ^{a,d,c}	3.30 (3.06–3.84) ^{a,d,c}	5.00 (4.34–5.45) ^{a,d,c}

Results are reported as median value (minimum-maximum range) n = 6.

^a Differences with HG_PF-F1NPs.

- ^b Differences with HG_PF-F2NPs.
- ^c Differences with HG_PF-F1NPs-Azone. ^d Differences with HC_PE-F2NPs-Azone
- ^d Differences with HG_PF-F2NPs-Azone. ^e Commercial eye drops.
- ^f Free drug solution.
- . ice ang solution.

Table 6

Amounts of PF permeated (Q_P) and retained (Q_R) across cornea and corneal hydration level (HL) from the HG_PF-NP formulations, commercial eye drops and free drug solution after 6 h.

Samples	<i>Q</i> _P (%/cm ²)	Q_R (%/cm ² g)	HL (%)
HG_PF-F1NPs	4.28 (3.6-4.93)	18.23 (15.21-19.61)	79.87 (76.18-80.03)
HG_PF-F2NPs	6.58 (5.35-7.08)	16.32 (16.17-16.64)	77.56 (77.25-79.80)
HG_PF-F1NPs-Azone	8.57 (7.20-9.59)	24.56 (23.38-25.57)	76.98 (76.57-78.87)
HG_PF-F2NPs-Azone	6.61 (8.51-8.17)	20.71 (16.64–24.60)	78.19 (77.87–79.67)
Eye drops	13.53 (11.12-13.57)	52.55 (51.23-53.62)	77.44 (78.23-79.87)
Free drug	13.62 (11.58-15.46)	50.41 (49.91-50.19)	78.12 (76.67-79.98)

Results are reported as median value and minimum – maximum range values (Q_P , n = 6; Q_R , n = 3; HL, n = 3).

8

G. Abrego et al./European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

639 formulations with or without azone (Table 6). Nevertheless, the 640 free drug solution is inherently irritating to the eye and addition-641 ally, pranoprofen is unstable in aqueous solution [42]. Otherwise, 642 the increased in the corneal permeation of pranoprofen showed 643 for the commercial eye drops can be explained due to this conventional dosage form has a combination of benzalkonium chloride 644 645 (BAK) and edetate disodium (EDTA). The BAK produces an increase 646 of the amount of drug permeating the cornea by disruption of the corneal epithelium. Additionally, it can also emulsify the corneal 647 epithelium, leading to increased partitioning of the drug [43]. 648 Moreover, EDTA also increases the corneal permeability of differ-649 650 ent drugs, by removing the extracellular calcium ions increasing tight junction permeability [22,44,45]. 651

Table 6 also shows that the Q_P and Q_R values of pranoprofen in 652 653 the cornea from the HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone 654 formulations are greater than those obtained from HG PF-F1NPs 655 and HG PF-F2NPs, respectively. The results suggest that the inclusion of azone into HG formulation leads to the increase in the 656 amount of drug permeated and retained. Azone is one of the most 657 widely studied penetration enhancers of hydrophilic and lipophilic 658 659 drugs, which can be used as a safe and effective penetration enhan-660 cer for human. Azone as a penetration enhancer is most effective at low percentages; values ranging from 1% to 3% had been reported 661 662 in the literature. Although azone has been used for over 25 years, 663 several researchers continue to investigate its mechanism of 664 action. The mechanism of azone may be related with modifications in the epithelial cell junctions and enhanced the influx of water 665 and the transcorneal penetration of hydrophilic drugs but delayed 666 667 the apparent drug permeation of lipophilic drugs through the cornea [22,23]. Regarding the corneal hydration analysis, the healthy 668 669 corneal has a hydration level of 76-80% [46]. According to the 670 results obtained in Table 6 for the HG_PF-NP formulations with 671 or without azone, commercial eye drops and free drug solution, 672 it can be concluded that during the assay the cornea was no 673 damage.

674 3.5. In vitro ocular tolerance

The studies using the HET-CAM are based on the direct application of the sample onto the chorioallantoic membrane and the observation of reactions, such as hemorrhage, intravasal coagulation or lysis of blood vessels [47]. The results of the HET-CAM test revealed optimal ocular tolerance of the HG_PF-NPs with or without azone since no irritation reactions were detected within 5 min of the assay (score 0).

682 3.6. In vivo ocular tolerance

Durand-Cavagna et al. evaluated in rabbits the ocular irritation 683 684 potential of 1% or 2% azone incorporated in ophthalmic vehicles, 685 such as poloxamer 188, hydroxyl-ethylcellulose, benzalkonium chloride and phosphate buffer. Signs of ocular irritation were 686 detected. However, the reported results were inconclusive since 687 irritation could not be attributed to the presence of azone or ben-688 689 zalkonium chloride [48]. In the present work, the irritancy of the optimized HG_PF-NP formulations with or without azone was 690 691 evaluated in New Zealand white rabbits. The results of Draize test showed good ocular tolerance of HG_PF-NPs with a 0% or 1% azone. 692 693 No signs of ocular irritancy were detected. These results are in 694 accordance with those obtained by HET-CAM test.

695 3.7. In vivo anti-inflammatory efficacy

Fig. 4 shows the anti-inflammatory efficacy effect of different
 formulations containing pranoprofen in the ocular edema induced
 by instillation of SA.




Fig. 4. Anti-inflammatory activity of PF from the HG_PF-F1NPs, HG_PF-F2NPs, HG_PF-F1NPs-Azone, HG_PF-F2NPs-Azone formulations, commercial eye drops and free drug solution. Mean \pm SD. n = 6.

Although the commercial eye drops and free drug solution show 699 the highest Q_R values of pranoprofen in the cornea, the anti-inflam-700 matory efficacy values obtained for the commercial eye drops are 701 lower compared to the other tested formulations (Fig. 4). Until 702 120 min, the free drug solution exhibits slower anti-inflammatory 703 activity than the HG_PF-NP formulation with or with azone. The 704 results obtained for the commercial eye drops and free drug solu-705 tion could be explained by the fact that these formulations show T_{I} 706 values greater than those obtained for the HG_PF-NPs with or 707 without azone. Thus, the commercial eye drops and free drug solu-708 tion reach slower steady state equilibrium than the HG_PF-NPs, 709 therefore show slower anti-inflammatory activity than the other 710 tested formulation. Fig. 4 also shows that the HG_PF-F1NPs-Azone 711 and HG_PF-F2NPs-Azone formulations significantly reduced the 712 ocular edema, compared to the HG_PF-F1NP and HG_PF-F2NP for-713 mulations, respectively. According to the results obtained in this 714 study, the inclusion of azone into the HG_PF-NP formulations leads 715 to the increase of the anti-inflammatory efficacy of pranoprofen in 716 the cornea. The anti-inflammatory efficacy values exhibited for the 717 HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone formulations are 718 correlated directly with the amount of drug retained in the cornea. 719 Therefore, the ocular application of the HG_PF-F1NPs-Azone or 720 HG_PF-F2NPs-Azone formulations could more effective in the 721 treatment of ocular edema that the HG_PF-F1NP or HG_PF-F2NP 722 formulations. 723

4. Conclusions

The optimized PF-F1NP and PF-F2NP suspensions were successfully dispersed into blank hydrogels or hydrogels containing 1% azone. The hydrogel formulations showed a rheological behavior and physicochemical properties suitable for ocular pranoprofen delivery. The HG_PF-NPs with or without azone exhibited sustained release behavior with a slower release of pranoprofen. According to the results obtained from the corneal permeation 731

724

G. Abrego et al./European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

732 and anti-inflammatory efficacy studies, the commercial eye drops 733 and free drug solution showed the highest Q_R values of pranopro-734 fen in the cornea. However, both formulations cannot be consid-735 ered optimal in the treatment of ocular diseases due to the free drug solution is inherently irritating to the eye and additionally, 736 pranoprofen is unstable in aqueous solution. Besides, following 737 738 the instillation of commercial eye drops, the most of the drugs is removed, by ear dilution and tear turn over from the surface of 739 the eye due to the low viscosity of these conventional dosage 740 forms. The HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone formula-741 tions significantly reduced the ocular edema, compared with other 742 tested formulations. These results indicate that the inclusion of 743 azone into the HG_PF-NP formulations leads to the increase of 744 the anti-inflammatory efficacy effect of pranoprofen in the cornea. 745 746 Therefore, the ocular application of these formulations could be 747 more effective in the treatment of ocular edema.

748 The HG PF-NPs with 0% or 1% azone showed an optimal ocular 749 tolerance by the in vitro e in vivo ocular irritation test. All these results suggest that the ocular administration of the HG_PF-750 F1NPs-Azone or HG_PF-F2NPs-Azone formulations could be an 751 752 effective and appropriate system for ophthalmic administration 753 of pranoprofen, improving the biopharmaceutical profile of this 754 drug, thus enhancing the local anti-inflammatory and analgesic 755 effect of this drug and, consequently, improving the patient's com-756 pliance. However, the formulations for ocular applications based 757 on carbomer hydrogels must be preserved in order to avoid the growth of microorganisms, but unfortunately the action of the 758 ophthalmic preservatives is non-specific and these can cause toxic-759 760 ity or damage to the ocular structure. In order to ensure the conser-761 vation of the HG_PF-NP formulation, additional studies related to 762 sterilization by autoclave or gamma irradiation would be required.

763 Conflict of interest

The authors declare that they have no conflict of interest.

765 Acknowledgments

766 G. Abrego wishes to acknowledge, the Spanish Ministry of For-767 eign Affairs and Cooperation and the Spanish Agency for Interna-768 tional Development Cooperation (MAEC-AECID) for a research 769 scholarship. The authors would also like to acknowledge the finan-770 cial support of the Spanish Ministry of Science and Innovation 771 (Grant MAT2011-26994), Portuguese Science and Technology 772 Foundation (FCT), and European funds (FEDER/COMPETE) under the reference PTDC/SAU-FAR/113100/2009. 773

774 Appendix A. Supplementary data

Supplementary data associated with this article can be found, in
 the online version, at http://dx.doi.org/10.1016/j.ejpb.2015.01.026.

777 **References**

785

786

787

788

789

790

791

- [1] I. Akyol-Salman, D. Leçe-Sertöz, O. Baykal, Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery, J. Ocul. Pharmacol. Ther. 23 (2007) 280–283.
- [2] M. Sawa, K. Masuda, M. Nakashima, Anti-inflammatory effect of diclofenac sodium eye drops on cataract surgery. Double masked study with pranoprofen eye drops, IOL RS 13 (1999) 193–200.
 [3] A.Z. McColgin, I.S. Heier, Control of intraocular inflammation associated with
 - [3] A.Z. McColgin, J.S. Heier, Control of intraocular inflammation associated with cataract surgery, Curr. Opin. Ophthalmol. 11 (2000) 3–6.
 - [4] X. Liu, S. Wang, A.A. Kao, Q. Long, The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes, Cornea 31 (2012) 1235–1239.
 - [5] R. Notivol, M. Martinez, M. Bergamini, Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group, Am. J. Ophthalmol. 117 (1994) 651–656.

- [6] M. Narashino, H. Ichikawa, S. Narita, A.S. Yotsukaido, Sustained-Release Pranoprofen Preparation, US00522506A, 1993.
- [7] K. Kobe, H. Otsu, Y. kobe, Y. Kakogawa, Method for Stabilizing Pranoprofen and Stable Liquid Preparation of Pranoprofen, United States Patent. US005856345A, 1999.
- [8] J. Araújo, E. Gonzalez, M.A. Egea, M.L. Garcia, E.B. Souto, Nanomedicines for ocular NSAIDs: safety on drug delivery, Nanomedicine: Nanotechnol. Biol. Med. 5 (2009) 394–401.
- [9] L.S. Nair, C.T. Laurencin, Biodegradable polymers as biomaterials, Prog. Polym. Sci. 32 (2007) 762–798.
- [10] A. Sabzevari, K. Adibkia, H. Hashemi, A. Hedayatfar, N. Mohsenzadeh, F. Atyabi, M.H. Ghahremani, R. Dinarvand, Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: *in vitro* and *in vivo* studies, Eur. J. Pharm. Biopharm. 84 (2013) 63–67.
- [11] E. Vega, M.A. Egea, M.L. Garduño-Ramírez, M.L. García, E. Sánchez, M. Espina, A.C. Calpena, Flurbiprofen PLGA-PEG nanospheres: role of hydroxy-βcyclodextrin on *ex vivo* human skin permeation and *in vivo* topical antiinflammatory efficacy, Colloids Surf. B. Biointerfaces 110 (2013) 339–346.
- [12] S.P. Ayalasomayajula, U.B. Kompella, Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model, Eur. J. Pharmacol. 511 (2005) 191–198.
- [13] T. Gratieri, G.M. Gelfuso, E.M. Rocha, V.H. Sarmento, O. de Freitas, R.F.V. Lopez, A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery, Eur. J. Pharm. Biopharm. 75 (2010) 186–193.
- [14] A. Lauterbach, C.C. Müller-Goymann, Comparison of rheological properties, follicular penetration, drug release, and permeation behavior of a novel topical drug delivery system and a conventional cream, Eur. J. Pharm. Biopharm., doi: 10.1016/j.ejpb.2014.10.001.
- [15] A. Zoppi, Y.G. Linck, G.a. Monti, D.B. Genovese, A.F. Jimenez Kairuz, R.H. Manzo, M.R. Longhi, Studies of pilocarpine:carbomer intermolecular interactions, Int. J. Pharm. 427 (2012) 252–259.
- [16] B. Buchan, G. Kay, A. Heneghan, K.H. Matthews, D. Cairns, Gel formulations for treatment of the ophthalmic complications in cystinosis, Int. J. Pharm. 392 (2010) 192–197.
- [17] P. Batheja, L. Sheihet, J. Kohn, A.J. Singer, B. Michniak-Kohn, Topical drug delivery by a polymeric nanosphere gel: Formulation optimization and *in vitro* and *in vivo* skin distribution studies, J. Control. Release. 149 (2011) 159–167.
- [18] F.E. Amara, M.E. Meleis, M.A. Seif, E.Y. Moursy, Study of the metabolic effect and histopathological nasal mucosal changes after prolonged intranasal insulin administration, J. Diabetol. 1 (2011) 1–10.
- [19] H. Fessi, F. Puisieux, J.P. Devissaguet, N. Ammoury, S. Benita, Nanocapsule formation by interfacial polymer deposition following solvent displacement, Int. J. Phar. 55 (1989) R1–R4.
- [20] G. Abrego, H.L. Alvarado, M.A. Egea, E. Gonzalez-Mira, A.C. Calpena, M.L. Garcia, Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of pranoprofen, J. Phar. Sci. 103 (2014) 3153–3164.
- [21] J.R. Robinson, Ocular drug delivery mechanism(s) of corneal drug transport and mucoadhesive delivery systems, STP Pharma 5 (1989) 839–846.
- [22] I.P. Kaur, R. Smitha, Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery, Drug Dev. Ind. Pharm. 28 (2002) 353– 369.
- [23] A.C. Williams, B.W. Barry, Penetration enhancers, Adv. Drug Deliv. Rev. 64 (2012) 128–137.
- [24] F. Lallemand, O. Felt-Baeyens, K. Besseghir, F. Behar-Cohen, R. Gurny, Cyclosporine A delivery to the eye: a pharmaceutical challenge, Eur. J. Pharm. Biopharm. 56 (2003) 307–318.
- [25] I.M. Ismail, C.C. Chen, J.B. Richman, J.S. Andersen, D.D. Tang-Liu, Comparison of azone and hexamethylene lauramide in toxicologic effects and penetration enhancement of cimetidine in rabbit eyes, Pharm. Res. 9 (1992) 817–818.
- [26] T.J. Franz, Percutaneous absorption. On the relevance of *in vitro* data, J. Investig. Dermatol. 64 (1975) 190–195.
- [27] P. Costa, J.M. Sousa, Modeling and comparison of dissolution profiles, Eur. J. Pharm. 13 (2001) (2001) 123–133.
- [28] K. Yamaoka, T. Nakagawa, T. Uno, Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations, J. Pharmacokinet. Biopharm. 6 (1978) 165–175.
- [29] N.P. Luepke, Heng's egg chorioallantoic membrane test for irritation potential, Food Chem. 23 (1985) 287–291.
- [30] M. Warren, K. Atkinson, S. Steer, Invittox-protocol: the Ergatt/Frame data bank of *in vitro* techniques in toxicology, Heńs egg test. Nr 15 (4) (1990) 707–710.
- [31] Journal Officiel de la République Française. Méthode Officiel d'evaluation du potentiel irritant par application sur la membrane chorioallantoidienne de l'oeuf de poule. Annexe IV. (1996) 1937–1938.
- [32] J. Draize, G. Woodard, H. Calvery, Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes, J. Pharmacol. Exp. Ther. 82 (1944) 377–390.
- [33] J.H. Kay, J.K. Calandra, Interpretation of eye irritation test, J. Soc. Cosmet. Chem. 13 (1962) 281–289.
- [34] S. Spampinato, A. Marino, C. Bucolo, M. Canossa, T. Bachetti, S. Mangiafico, Effects of sodium naproxen eye drops on rabbit ocular inflammation induced by sodium arachidonate, J. Ocul. Pharmacol. 7 (1991) 125–133.
- [35] E. Gonzalez-Mira, S. Nikolić, A.C. Calpena, M.A. Egea, E.B. Souto, M.L. Garcia, Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels, J. Pharm. Sci. 101 (2012) 707–725.

Please cite this article in press as: G. Abrego et al., Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration, Eur. J. Pharm. Biopharm. (2015), http://dx.doi.org/10.1016/j.ejpb.2015.01.026

792

793

794

834

835

836

837

838

839

840

841 842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860 861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

16 February 2015

10

881

882

883

884

885

886

887

888

889

890

891

892

G. Abrego et al./European Journal of Pharmaceutics and Biopharmaceutics xxx (2015) xxx-xxx

- [36] A. Zimmer, J. Kreuter, Microspheres and nanoparticles used in ocular delivery systems, Ocul. Drug Deliv. Rev. 168 (1995) 61–73.
 [37] X. Song, Y. Zhao, S. Hou, F. Xu, R. Zhao, L. He, Z. Cai, Y. Li, O. Chen, Dual agents.
 - [37] X. Song, Y. Zhao, S. Hou, F. Xu, R. Zhao, J. He, Z. Cai, Y. Li, Q. Chen, Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency, Eur. J Pharm. Biopharm. 69 (2008) 445–453.
 - [38] F. Han, R. Yin, X. Che, J. Yuan, Y. Cui, H. Yin, S. Li, Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and *in vivo* evaluation, Int. J. Pharm. 439 (2012) 349–357.
 - [39] Malvern Instruments. 10 Ways to Control Rheology by Changing Particles Properties. INFORM Series of White Papers, 2009.
 - [40] S.K. Sahoo, J. Panyam, S. Prabha, V. Labhasetwar, Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake, J. Control Release 82 (2002) 105–114.
 - [41] M. Hamidi, A. Azadi, P. Rafiei, Hydrogel nanoparticles in drug delivery, Adv. Drug Deliv. Rev. 60 (2008) 1638–1649.

- [42] M. Ahuja, A.S. Dhake, S.K. Sharma, D.K. Majumdar, Topical ocular delivery of NSAIDs, AAPS J. 10 (2008) 229–241.
- [43] M.S. Rathore, D.K. Majumdar, Effect of formulation factors on *in vitro* transcorneal permeation of gatifloxacin from aqueous drops, AAPS PharmSciTech. 7 (2006) E1–E6.
- [44] K. Järvinen, T. Järvinen, A. Urtti, Ocular absorption following topical delivery, Adv. Drug Deliv. Rev. 16 (1995) 3–19.
- [45] P. Furrer, J.M. Mayer, R. Gurny, Ocular tolerance of preservatives and alternatives, Eur. J. Pharm. Biopharm. 53 (2002) 263–280.
- [46] R.D. Schoenwald, H.S. Huang, Corneal penetration behavior of beta-blocking agents I: physiochemical factors, J. Pharm. Sci. 72 (1983) 1266–1272.
 [47] J. Tavaszi, P. Budai, The use of HET-CAM test in detecting the ocular irritation,
- Commun. Agric. Appl. Biol. Sci. 72 (2007) 137–144.
 Courand Guarga D. Ducast S. Malan Nablet D. Dalart A. Basia: Courant
- [48] G. Durand-Cavagna, P. Duprat, S. Molon-Noblot, P. Delort, A. Rozier, Corneal endothelial changes with Azone, a penetration enhancer, Lens Eye Toxic. Res. 6 (1989) 109–117.

893

894